logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals sees 1Q revenue soar 76% driven by impressive sales momentum

For its first quarter ended March 31, Aequus reported revenue of C$579,450, a 76% increase in revenue compared to the first quarter of 2019

Aequus Pharmaceuticals Inc. -
In a positive, the company narrowed its loss to C$405,815, from a loss of C$730,215 in the first quarter of 2019

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) posted first-quarter results on Monday that saw its revenue jump 76% year-over-year on the back of greater market access and higher sales volume.

The Vancouver-based specialty pharmaceutical company has several commercial products in the ophthalmology and transplant space. It also boasts a development stage pipeline of drugs in neurology and psychiatry.

READ: Aequus Pharmaceuticals posts 44% rise in 4Q revenue rounding out solid financial gains in 2019

In a statement accompanying the numbers, Aequus Pharmaceuticals CEO Doug Janzen, said: "Today, the company reported record quarterly revenues of C$579,450 for the first quarter of 2020, a 76% increase in revenues compared to the first quarter in 2019."

"We ended 2019 with strong sales momentum and are pleased to report a record quarter in Q1 2020, almost doubling revenues over the same period 12 months ago," he added.

Janzen put the strong revenue growth down to the company's greater market access and higher sales volume.

"We also have progressed our launch plans for the Evolve line up of dry-eye products and recently completed a large patient and physician engagement survey which gave us a positive indication of demand and has provided us the insights necessary for a successful launch," he added.

In its first quarter ended March 31, Aequus reported a loss of C$405,815, down from a loss of C$730,215 in the first quarter of 2019, mainly due to higher sales and a decrease in expenses.

Research and marketing expenses were lower as the firm focused on growing commercial revenues, while sales and marketing expenses were down as doctors were not accessible due to the coronavirus, while the company's field representatives were not able to travel to see customers in person from March due to the coronavirus lockdown.

In Monday' statement, the group clarified that on May 2, 2019, the company issued convertible debenture units for gross proceeds of $2,348,000.

Contact the author at [email protected]

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.08 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $6.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Aequus Pharmaceuticals off to a great start in 2020 after...

Aequus Pharmaceuticals (CVE:AQS-OTCQB: AQSZF) Chairman and CEO Doug Janzen joined Steve Darling from Proactive Vancouver as the company released their 2019 financial numbers which saw Aequus set a revenue record in the 4th quarter. Janzen also discussed 2020 and where he sees the best...

on 05/04/2020

2 min read